Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6798)	6/22/1999 1:58:00 AM
From: Vector1	Respond to of 9719

GLIA is a classic Rick pick. The current approved product, in this case Adcon, justifies the $220 million market cap. The earlier stage stuff is all upside with low risk because of the existing revenue stream. Nice leveraged business plan. Looks like Adcon will do 30-35m this year with good potential growth from add-on applications such as breast augmentation surgery. G&A and sales cost is in line and margins are around 85%, making growth over the current run rate highly profitable. One constraint on growth will be Medicaid and insurance reimbursement. Adcon adds about $500 to the cost of the procedure. IF the hospitals are not reimbursed they will not use it. Such is the state of medical care in the US as we approach the millenium. What is the company doing to ensure insurance coverage. V1